Cancer Research Targets Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsukahara, T.
Right arrow Articles by Sato, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsukahara, T.
Right arrow Articles by Sato, N.
[Cancer Research 64, 5442-5448, August 1, 2004]
© 2004 American Association for Cancer Research

Immunology

Identification of Human Autologous Cytotoxic T-Lymphocyte-Defined Osteosarcoma Gene That Encodes a Transcriptional Regulator, Papillomavirus Binding Factor

Tomohide Tsukahara1, Yuki Nabeta1, Satoshi Kawaguchi1, Hideyuki Ikeda3, Yuriko Sato1, Kumiko Shimozawa4, Kazunori Ida1, Hiroko Asanuma3, Yoshihiko Hirohashi2, Toshihiko Torigoe2, Hiroaki Hiraga5, Satoshi Nagoya1, Takuro Wada1, Toshihiko Yamashita1 and Noriyuki Sato2

1 Departments of Orthopedic Surgery and 2 Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan; 3 Division of Clinical Pathology, Sapporo Medical University, Sapporo, Japan; 4 Cancer Vaccine Laboratory, Japan Science and Technology Corporation, Sapporo, Japan; and 5 Department of Clinical Research, Division of Orthopedics, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The prognosis for patients with osteosarcoma who do not respond to current chemotherapy protocols still remains poor. Toward the goal of establishing efficacious peptide-based immunotherapy for those patients, we previously developed an autologous pair of CTLs and an osteosarcoma cell line. In the current study, we screened the cDNA library of this osteosarcoma cell line using an autologous CTL clone and identified cDNA encoding an antigen. The isolated cDNA was identical to papillomavirus binding factor (PBF), which was recently reported as a DNA binding transcription factor cooperating with RUNX1. Reverse transcription-PCR analysis revealed that PBF was expressed in 16 of 19 cases of bone and soft-tissue sarcoma cell lines (5 of 6 of osteosarcoma lines) and 57 of 76 sarcoma tissue samples (11 of 14 of osteosarcoma tissues). Also, PBF was expressed in 10 of 13 epithelial cancer cell lines and 20 of 34 of cancer tissues. In contrast, PBF was detected in some normal organs including ovary, pancreas, spleen, and liver by reverse transcription-PCR but was restricted in the cytoplasm by immunostaining and undetectable by Western blotting. Furthermore, a 12-mer peptide, CTACRWKKACQR, located at the COOH terminus of PBF, was found to be a minimum requirement for recognition by the CTL clone in the context of the HLA-B*5502 molecule. These findings suggest that PBF is a shared tumor-associated antigen, which may serve as a source of peptides applicable to peptide-based immunotherapy for osteosarcoma and other malignant tumors.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Osteosarcoma is the most common primary malignant bone tumor of childhood and adolescence (1) . Despite the advent of combined surgical and chemotherapeutic modalities, 30–40% of patients with osteosarcoma still succumb to metastatic diseases (2) . For those patients, development of new therapeutic modalities is urgently needed.

Currently, there is a growing realization that active immunotherapy serves as the fourth therapeutic modality for malignant tumors following surgery, chemotherapy, and radiotherapy. The identification of tumor-associated antigens recognized by CTLs and subsequent clinical trials using peptide vaccine formulations derived from those antigens have shown tumor regression in patients with malignant melanoma and several carcinomas (3 , 4) . Meanwhile, no such antigens have yet been identified in osteosarcoma, even though CTLs reacting with autologous osteosarcoma cells were successfully developed by Slovin et al. (5) more than a decade ago. The reasons for this delay include the following: (a) relatively low immunogenicity of osteosarcoma because there are few examples of spontaneous tumor regression and tumor-infiltrating lymphocytes (6 , 7) ; (b) the practical difficulty in establishing osteosarcoma cell lines and autologous CTLs (5 , 8) ; and (c) the lack of suitable candidate genes for a reverse immunological approach such as a tumor-specific fusion gene (9 , 10) . An alternative proposal to use peptides derived from known shared antigens in antiosteosarcoma immunotherapy such as MAGE-3 and SART-1 (11 , 12) requires preclinical evaluation of peptide antigenicity.

After attempts over a period of 3 years, we recently established an autologous tumor cell-CTL pair from a 16-year-old osteosarcoma patient (8) . Using this pair in the present study, we carried out cDNA library expression cloning and identified an antigen and an epitope that sensitize the antiautologous osteosarcoma CTL clone.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
This study was approved under the institutional guidelines for the use of human subjects in research. Patients and/or their families gave informed consent for use of tissue specimens and blood samples in research.

Cell Lines and Transfectants.
Cell lines used were osteosarcoma (OS2000, KIKU, Huo9, NY, HOS, and Saos2), Ewing’s sarcoma (A673, W-ES, NCR-EW2, SCCH196, SK-ES1, and RD-ES1), synovial sarcoma [HS-SY-II (13) ; SW982 and Fuji (14) ], rhabdomyosarcoma (HS729T, A204, and RD), fibrosarcoma (HT1080), lung adenocarcinoma (LHK-2 and KMG-A), head and neck squamous cell carcinoma (Fs-1, OSC20, OSC4, and HC-MA), esophageal carcinoma (KE-4), malignant melanoma (LG2-mel, LB33-mel, 888-mel, and 1102-mel), renal cell carcinoma (BB64-RCC), bladder carcinoma (LB905-BLC), and erythroleukemia (K562). EBV-infected B-cell lines (LG2-EBV and OS2000-EBV) and 293EBNA cells were also used. OS2000, KIKU, and LHK-2 cell lines were established in our laboratory (8 , 15) . Other cell lines were kindly donated or purchased from the Japanese Collection of Research Bioresources Cell Bank (Tokyo, Japan), Invitrogen Corp. (Carlsbad, CA), and American Type Culture Collection (Manassas, VA). HLA genotypes of osteosarcoma cell lines were as follows: (a) OS2000, A*2402, B*5502, B*4002, Cw*0102; (b) KIKU, A*2402, A*0206, B*4006, B*5201, Cw*0801, Cw*1202; (c) Huo9, A*2401, A*3303, B*44031, B*5101, Cw*1402, Cw*1403; (d) NY, A*2601, B*5502, Cw*0303; and (e) HOS, A*0211, B*5201, Cw*1202.

HOS cells and 293EBNA cells were transfected with the expression vector pIRESpuro (BD Biosciences Clontech, Palo Alto, CA) encoding cDNA for HLA-B*5502, which had been subcloned from OS2000 cDNA. HOS transfectants were selected in RPMI 1640 containing puromycin (1 µg/ml), and 293EBNA transfectants were selected in DMEM containing neomycin (375 µg/ml) and puromycin (2 µg/ml). Stable transfectants were designated as HOS-B55 and 293EBNA-B55, respectively.

Antibodies.
Monoclonal antibodies used were anti-HLA class I monoclonal antibody [mAb (W6/32; isotype IgG2a)] anti-HLA-A24 mAb (C7709A2.6; IgG2a) (16) , and anti-HLA-B55 mAb [ME1; IgG1 as anti-HLA-B7-B27-Bw22 (B54, B55, and B56)]. Those hybridomas were kindly donated or purchased from American Type Culture Collection.

Establishment of Autologous CTL Clones.
Autologous CTLs derived from peripheral blood mononuclear cells against OS2000 cells (8) were plated at various dilutions in round-bottomed 96 microwells (Corning, Inc., Corning, NY) in AIM-V supplemented with recombinant interleukin-2 (20 units/ml; a gift from Takeda Chemical Industries, Ltd., Osaka, Japan) and anti-CD3 antibody (40 ng/ml; BD Biosciences PharMingen, San Diego, CA). LG2-EBV cells (1 x 104 cells/well) and allogeneic irradiated peripheral blood mononuclear cells (1.5 x 106 cells/well) were added as feeder cells. Cells were incubated at 37°C, and the medium was switched to AIM-V supplemented with 1000 units/ml recombinant interleukin-2 on day 10. CTL clones showing specific cytotoxicity against OS2000 cells in a standard 6-h 51Cr release assay (17 , 18) were selected and designated TcOScl-101, TcOScl-301, and TcOScl-303. In experiments to evaluate the effects of IFN-{gamma}, OS2000 cells were cultured with 100 units/ml IFN-{gamma} (a gift from Shionogi & Co., Ltd., Osaka, Japan) for 48 h at 37°C before 51Cr release assay.

Lactate Dehydrogenase (LDH) Release Assay.
Target cells were plated in flat-bottomed 96 microwells (Corning, Inc.) and incubated at 37°C for 24 h. Supernatants were then discarded, and 8 x 104 TcOScl-303 cells were added. After a 24-h incubation in AIM-V medium at 37°C, the amount of LDH in supernatant (100 µl) was measured by colorimetric assay using a LDH Cytotoxicity Detection Kit (Takara, Ohtsu, Japan). OS2000 cells were used as a control target. Cytotoxicity was calculated using the following equation: LDH release = (sample release on incubation with CTL – spontaneous release on incubation with medium)/(OS2000 release on incubation with CTL – spontaneous release on incubation with medium).

In blocking experiments, mAb (W6/32, C7709A2.6, or ME1) was added and incubated for 30 min at room temperature before coculture with TcOScl-303 cells. In experiments to determine the antigenicity of peptides, 293EBNA-B55 cells (8 x 104) were pulsed with 1 mg/ml peptide and DTT (200 µM) for 1 h at 37°C before incubation with TcOScl-303 cells.

cDNA Library Expression Cloning.
A cDNA library was prepared from OS2000 mRNA using FastTrack 2.0 mRNA Isolation Kit (Invitrogen) and the Superscript Choice System (Invitrogen). The cDNA was ligated to HindIII-NotI adapters and digested by NotI. The resultant cDNA was cloned into the pCEP4 vector (Invitrogen). Recombinant plasmids were electroporated into ELECTROMAX DH10B cells (Invitrogen) and selected with ampicillin (100 µg/ml). The library was divided into pools of 100–150 cDNA clones. Each pool was amplified, and plasmid DNA was extracted using a QIAprep8 turbo Miniprep kit (Qiagen, Hilden, Germany). 293EBNA-B55 cells (8 x 104 cells/well) were transfected with cDNA (100–200 ng) using LipofectAMINE 2000 (0.4 µl) in DMEM containing 10% FCS in flat-bottomed 96 microwells (Corning, Inc.) at 37°C for 24 h. Then, TcOScl-303 cells (8 x 104 cells/well) were added, and the medium was replaced by AIM-V. After a 24-h incubation at 37°C, the amount of LDH in the supernatant was measured for colorimetric assay. The screening was performed in duplicate. Positive clones were selected on the basis of LDH release, and their sequence was referred to the GenBank database.

Reverse Transcription-PCR (RT-PCR) Analysis.
Expression of PBF in tumor cell lines and tissue specimens was determined by RT-PCR. Tumor cell lines used were described earlier. Biopsy specimens of sarcoma included 20 cases of synovial sarcomas, 14 osteosarcomas, 12 Ewing’s sarcomas, 8 malignant fibrous histiocytomas, 8 malignant peripheral nerve sheath tumors, and 5 liposarcomas (19) . Also, three cases each of rhabdomyosarcoma, leiomyosarcoma, and clear cell sarcoma were included (19) . Biopsy specimens of carcinoma included 10 lung cancers (3 adenocarcinomas, 2 large cell carcinomas, and 5 squamous cell carcinomas), 9 gastric cancers, 7 colorectal cancers, 5 breast cancers, 1 pancreatic cancer, and 1 case of uterine corpus cancer. Normal tissue cDNAs were purchased (Multiple Tissue cDNA Panels; BD Biosciences Clontech). Total RNA was extracted from cell lines and tissue specimens and reverse transcribed. PCR was performed with KOD dash DNA polymerase (Toyobo, Tokyo, Japan), using forward primer 5'-GGAGGATTTCTACTACACAG-3' and reverse primer 5'-AAATATGCGGCCGCGGCCAGGAACAGAGTAGAAC-3'. The mixture was denatured at 98°C for 2 min, followed by 30 cycles at 98°C for 15 s, 56°C for 2 s, and 74°C for 1 min. Reaction products were analyzed by electrophoresis in 1.0% agarose gels with ethidium bromide.

Immunohistochemistry.
Polyclonal antibody against PBF was generated by immunizing rabbits with a 15-mer peptide, CGDTVDSDQFKREED, once per week for 6 weeks. The serum was purified by using Protein A column (SigmaGenosys, Sapporo, Japan). Formalin-fixed paraffin-embedded sections of osteosarcoma biopsy specimens including the origin of OS2000 and autopsy specimens of pancreas, spleen, and ovary (obtained from a brain infarction patient) were deparaffinized and then boiled by microwave for antigen retrieval. The sections were blocked and stained by the standard avidin-biotin complex method (20) . Hematoxylin was used for counterstaining.

Western Blotting.
Normal tissue lysates were purchased from BD Biosciences Clontech and Nippon Gene. Cell lines and biopsy specimens were homogenized and suspended in ice-cold radioimmunoprecipitation assay buffer for 20 min. The lysates were mixed with 2x sample buffer and boiled for 5 min. Then the lysates were separated on 7% SDS-polyacrylamide gels and transferred to a polyvinylidene fluoride membrane (Millipore, Billercia, MA). The membranes were blocked and probed with anti-PBF antibody (100 µg/ml) or mouse anti-ß-actin monoclonal antibody (clone AC-15; 1:1000 dilution; Sigma), for 40 min at room temperature, respectively. Then the membranes were stained with peroxidase-labeled secondary antibody and visualized using an enhanced chemiluminescence detection system (Amersham Life Science, Arlington Heights, IL).

Construction of Variants and Synthetic Peptides from PBF cDNA.
The cDNA for the longest open reading frame of PBF was cloned from the OS2000 cDNA into myc-tagged pcDNA3.1(+) (PBF/pcDNA3.1) at the BamHI-XhoI site, using forward primer 5'-CGCGGATCCATGGCGAGTGTCCTGTCC-3' and reverse primer 5'-CGGCTCGAGGGCCAGGAACAGAGTAGAAC-3'. The mixture was denatured at 94°C for 2 min, followed by 35 cycles at 94°C for 15 s, 57°C for 30 s, and 68°C for 3 min. Truncated cDNA variants and amino acid substitution variants (one codon was replaced with alanine- or serine-encoding codon) of PBF were generated by PCR and subcloned into pCEP4. Antigenicity of each synthetic peptide was evaluated by LDH release assay.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Cytotoxicity and HLA Restriction of the Autologous TcOScl-303 Clone.
To attain the goal of establishing efficacious peptide immunotherapy for patients with osteosarcoma, we developed an autologous pair of CTLs and an osteosarcoma cell line, OS2000, from a 16-year-old patient. In the current study, we cloned those CTLs by limiting dilution and obtained TcOScl-301, TcOScl-303, and TcOScl-101. Of these three clones, TcOScl-303 showed the highest cytotoxicity against OS2000 cells and was therefore used again in subsequent experiments. As shown in Fig. 1ACitation , the TcOScl-303 clone lysed OS2000 cells, but not 293EBNA or K562 cells, as determined by 6-h 51Cr release assays. In addition, cytotoxicity of TcOScl-303 against OS2000 cells was enhanced by pretreatment with IFN-{gamma}. The phenotype of TcOScl-303, as determined by flow cytometry, was CD3+, CD4–, CD8+, and T-cell receptor positive (data not shown).



View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Cytotoxicity of a CTL clone, TcOScl-303, against autologous and allogeneic osteosarcoma cell lines. A, cytotoxicity of TcOScl-303 against the autologous osteosarcoma cell line OS2000 and K562 and 293EBNA cells was assessed by a 6-h standard 51Cr release assay at the indicated E:T ratios. OS2000 cells were assayed in the presence or absence of IFN-{gamma}-pretreatment. B, cytotoxicity of TcOScl-303 against allogeneic osteosarcoma cell lines (NY, KIKU, and Huo9) was assessed by a 51Cr release assay. The left panel indicates the expression profile of HLA-A*2402 and HLA-B*5502 in the target cells used. Right panel, percentage of specific lysis. C, cytotoxicity of TcOScl-303 was also assessed in a lactate dehydrogenase release assay. OS2000, NY, HOS (allogeneic osteosarcoma cell line), and HOS-B55 (HLA-B*5502 transfectant) were used as target cells. The left panel indicates the expression profile of HLA-B*5502 in the target cells and E:T ratios used in the assay. Right panel, lactate dehydrogenase release.

 
To determine HLA restriction, we evaluated the cytotoxicity of TcOScl-303 against allogeneic osteosarcoma cell lines (Fig. 1B)Citation . As shown, TcOScl-303 selectively lysed OS2000 and NY cells, both of which express HLA-B*5502. To further confirm the HLA-B*5502 restriction of TcOScl-303 cytotoxicity, we generated HLA-B*5502-transfected HOS cells (HOS-B55). As shown in Fig. 1CCitation , cytotoxicity of TcOScl-303 against HOS cells increased by exogenous expression of HLA-B*5502. These findings suggest that TcOScl-303 recognized putative shared antigens presented by the HLA-B*5502 molecule.

Cloning of cDNA Encoding an Osteosarcoma Antigen Recognized by the TcOScl-303 Clone.
We then screened 1000 pools (1 x 105 cDNA clones) of the cDNA library constructed from OS2000 mRNA by a LDH assay using HLA-B*5502-transfected 293EBNA (293EBNA-B55) cells and the TcOScl-303 clone. Consequently, we identified four positive clones, all of which contained an identical cDNA fragment. Fig. 2ACitation shows representative results of a positive clone, 1B9.1H4. TcOScl-303 clone selectively lysed 293EBNA-B55 cells transfected with 1B9.1H4 cDNA and the original OS2000 cells. Standard 51Cr release assays also confirmed the specific recognition of TcOScl-303 for 1B9.1H4 cDNA (Fig. 2B)Citation .



View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Recognition of a cDNA clone, 1B9.1H4, by TcOScl-303. A, screening of the OS2000 cDNA library by lactate dehydrogenase assays identified a cDNA clone, 1B9.1H4, which was recognized by TcOScl-303 in the context of HLA-B*5502. 1B9.1H4 consisted of a long open reading frame of papillomavirus binding factor (PBF) with deletion of 5' sequence and additional 3'-untranslated region. Hence, PBF also conferred TcOScl-303 a response. B, recognition of 1B9.1H4 by TcOScl-303 was also examined by a 51Cr release assay. 293EBNA-B55 cells were transiently transfected with 200 ng of cDNA of 1B9.1H4 or vector (pCEP4). After a 48-h incubation, 293EBNA-B55 cells were collected and labeled with 51Cr, followed by incubation with TcOScl-303 at the indicated E:T ratio for 6 h. K562 cells were used as negative control. C, inhibitory effects of monoclonal antibodies on recognition of PBF by TcOScl-303 were examined. 293EBNA-B55 cells (8 x 104) were transiently transfected with 200 ng of PBF cDNA and incubated with TcOScl-303 (8 x 104) in the presence or absence of monoclonal antibody W6/32 (anti-HLA-class I), C7709A2.6 (anti-HLA-A24), or ME1 (anti-HLA-B55). Lactate dehydrogenase released in the media was measured after 24 h.

 
Structure of cDNA 1B9.1H4 Identical to PBF.
The 1B9.1H4 clone contained 1908-bp cDNA, which was identical to the longest open reading frame of PBF (21) with deletion of 5' sequence and additional 3'-untranslated region. There were no frameshifts or point mutations. Subsequently, we examined the antigenicity of PBF for TcOScl-303. As shown in Fig. 2ACitation , TcOScl-303 selectively lysed 293EBNA-B55 cells transfected with cDNA for wild-type PBF or 1B9.1H4 cDNA, in addition to OS2000 cells. Furthermore, lysis by TcOScl-303 was blocked by anti-HLA-B55 mAb and anti-HLA-class I mAb, but not by anti-HLA-A24 mAb (Fig. 2C)Citation , suggesting HLA-B*5502 restriction in recognition of PBF by TcOScl-303.

Expression of PBF in Tumors and Normal Organs.
We next determined the expression of PBF in various tumors and normal tissues by RT-PCR, immunohistochemical staining, and Western blotting. Table 1Citation summarizes the results of RT-PCR analysis in bone and soft-tissue sarcomas. As shown, PBF was detected in 16 of 19 (84%) bone and soft-tissue sarcoma cell lines and 57 of 76 (75%) sarcoma tissue samples. With regard to osteosarcoma, PBF was detectable in 5 of 6 cell lines and 11 of 14 biopsy specimens (Fig. 3A)Citation . Table 2Citation summarizes the expression of PBF in epithelial cancer cell lines and tissues, showing positive PCR in 10 of 13 (77%) and 20 of 34 (59%) cases, respectively. In normal adult organs (Fig. 3B)Citation , PBF was detectable in the pancreas and ovary at substantial reactivity; however, PBF expression was weaker in the prostate, heart, liver, spleen, thymus, and testis and faint or undetectable in other organs. None of the fetal normal organs showed significant PBF product, although the pancreas and ovary were not included in the analysis.


View this table:
[in this window]
[in a new window]

  		Table 1 PBFa expression in sarcoma cell lines and primary sarcoma tissues

 


View larger version (34K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Expression of papillomavirus binding factor (PBF) mRNA in osteosarcoma and normal tissues. A, reverse transcription-PCR analysis. The expression of PBF was determined in autologous cells (PBL, peripheral lymphocyte line; OS2000 EBV; B-cell line transformed with EBV), K562 cells, 293EBNA (293) cells, 5 osteosarcoma cell lines, and 14 osteosarcoma tissues. The glyceraldehyde-3-phosphate dehydrogenase (G3PDH) housekeeping gene was used as positive control. B, reverse transcription-PCR analysis. The expression of PBF was determined in 16 adult and 8 fetal normal tissues. The glyceraldehyde-3-phosphate dehydrogenase (G3PDH) housekeeping gene was used as a positive control.

 

View this table:
[in this window]
[in a new window]

  		Table 2 PBFa expression in epithelial cancer cell lines and primary cancer tissues

 
For immunohistochemical analysis and Western blotting, we developed an anti-PBF polyclonal antibody. As shown in Fig. 4ACitation , anti-PBF antibody reacted strongly with the nuclei of osteosarcoma tissues. In contrast, reactivity of the antibody was weak and restricted to the cytoplasm in tissue specimens of pancreas, spleen, and liver. The other osteosarcoma and normal tissues showed a similar staining pattern (data not shown).



View larger version (83K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Expression of papillomavirus binding factor (PBF) protein in sarcomas and normal tissues. A, immunostaining. PBF expression was determined in two osteosarcomas (left column indicates the origin of OS2000) and in pancreatic, ovarian, and spleen specimens using preimmune rabbit sera and anti-PBF polyclonal antibody. Original magnification was x200. Insets, high magnification fields (x400). B, Western blotting. PBF expression was determined in primary sarcoma tissues (osteosarcoma and Ewing’s sarcoma) and eight normal tissues using anti-PBF polyclonal antibody. The lysate of 293EBNA cells transfected with PBF or mock-transfected was used as control sample. PBF protein was detected as a single Mr 80,000 band.

 
In Western blotting analysis (Fig. 4B)Citation , anti-PBF antibody reacted with lysate of 293EBNA cells transfected with PBF cDNA and OS2000 cells, OS2000 tumor tissue, and Ewing’s sarcoma tissue. In contrast, no detectable reaction was observed in the lysate of normal tissues.

Identification of Epitope for TcOScl-303 Clone.
Finally, we attempted to determine the epitope of PBF recognized by the TcOScl-303 CTL clone. A number of truncated variants of PBF were transfected into 293EBNA-B55 cells and tested for TcOScl-303 recognition by LDH release assay. As shown in Fig. 5ACitation , TcOScl-303 lysed 293EBNA-B55 cells when they were transfected with PBF variants containing the COOH-terminal end at 1866 bp or longer. In contrast, cytotoxic activity clearly fell when the COOH-terminal end of PBF was truncated at 1863 bp.



View larger version (23K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Epitope mapping in papillomavirus binding factor (PBF) recognized by TcOScl-303. A, left panel, a structural summary of PBF and its truncated variants. Right panel, responses of TcOScl-303 against controls and these variants transfected in 293EBNA-B55 cells. The nucleotide and amino acid sequence of the COOH terminus of PBF are described at the bottom of the left panel. B, left panel, the COOH-terminal amino acid sequence of PBF 337-1866 bp and its amino acid substitution variants (one codon was replaced with Ala- or Ser-encoding codon). For example, R510A indicates that the codon encoding Arg was substituted with an Ala-encoding codon at position 510 on PBF 337-1866-bp plasmid. Right panel, responses of TcOScl-303. C, synthetic peptides derived from the COOH terminus of PBF were pulsed with 293EBNA-B55 cells and tested for TcOScl-303 recognition by lactate dehydrogenase release assay. Left panel indicates amino acid sequence of the synthetic peptides. Right panel, lactate dehydrogenase release.

 
To further assess the antigenicity of the COOH-terminal region (337–1866 bp) of PBF, we substituted one codon at the terminus of this region with Ala- or Ser-encoding codon and tested for TcOScl-303 recognition in 293EBNA-B55 cells. As shown in Fig. 5BCitation , substitutions of Arg at position 510 and Gln at position 509 did not particularly affect recognition by TcOScl-303. In sharp contrast, substitution of Cys at position 508 apparently reduced the amount of LDH release. A similar apparent reduction in LDH release was observed by substitutions of Cys at position 502 and Ser at position 501.

On these findings, we tested the antigenicity of various synthetic peptides for the TcOScl-303 clone, focusing on the COOH-terminal end of PBF (501–510 amino acids). Of these, the 12-mer peptide CTACRWKKACQR (499–510 amino acids) was the most immunogenic for TcOScl-303 in the context of HLA-B*5502 (Fig. 5C)Citation .


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In the present study, we identified PBF as an osteosarcoma antigen recognized by autologous CTLs using the cDNA expression cloning procedure. We found that a 12-mer peptide, CTACRWKKACQR, located at the COOH terminus of PBF was a minimum requirement for recognition by TcOScl-303 in the context of the HLA-B*5502 molecule. These findings suggest that PBF may serve as a source of therapeutic peptides that are effective in further improving survival rates of patients with osteosarcoma, especially those who are unresponsive to current chemotherapy protocols.

Tumor-associated antigen recognized by CTLs is the principal prerequisite for the development of antigen-specific cancer immunotherapy. However, given the technical difficulty in establishing autologous tumor-CTL pairs, antigen identification based on autologous pairs has come mostly from melanoma and renal cell carcinoma. In other tumors, including bone and soft-tissue sarcomas, a reverse immunology approach has been used and has defined antigenic peptides from tumor-specific fusion genes such as SYT-SSX in synovial sarcoma (9 , 10) , EWS-FLI1 in Ewing’s sarcoma (22) , and PAX3-FKHR in alveolar rhabdomyosarcoma (10 , 22) . Because the peptides defined by the reverse approach are not always processed in tumor cells, those synthetic peptides need rigorous evaluation before clinical application. In addition, their therapeutic efficacy may not be as promising as those defined by the autologous pair-based approach. In fact, vaccination trials of junction peptides from BCR-ABL [12 patients with chronic myelogenous leukemia (23) ], EWS-FLI1 [12 patients with Ewing’s sarcoma (22) ], and PAX3-FKHR [four patients with alveolar rhabdomyosarcoma (22) ] only resulted in tumor remission in a single patient with Ewing’s sarcoma.

We used the LDH release assay to screen the cDNA library, even though this method is not as common as cytokine release assays. In our hands, none of cytokine release assays (IFN-{gamma}, TNF-{alpha}, and GM-CSF) sucessfully detected the specific CTL responses against OS2000 cells due to spontaneous cytokine release from the TcOScl-303 CTL clone. The value and reproducibility of LDH release assay have been confirmed by 51Cr release assays in the present study and have also been confirmed by other investigators (24 , 25) .

The clone isolated from a cDNA expression cloning procedure was identical to PBF, a newly defined transcription factor (21) . PBF has been shown to regulate E2-mediated repression of genomic DNA of human papillomavirus type 8 in cooperation with RUNX1. The role of PBF in bone and soft-tissue sarcomas remains uncertain. We can only speculate that the functional cooperation between PBF and the RUNX family members (RUNX1, RUNX2, and RUNX3) may also exist in sarcomas because these members have been shown to play pivotal roles during normal development and in oncogenesis (26 , 27) . Notably, RUNX1 has been shown to be involved in the differentiation of osteochondroprogenitor cells (28) , and RUNX2 (also known as CBFA1) functions as a master regulatory gene for osteoblastogenesis.

The peptide defined as the CTL epitope was unexpectedly a 12-mer form and had to be of a high concentration (1 mg/ml) for optimal sensitization. Such long antigenic peptides have been reported in the literature (29, 30, 31, 32, 33, 34, 35) . Without peptide elusion or structural analysis, we are not able to comment on whether the 12-mer peptide is identical to the natural ligand presented by HLA-B*5502 on OS2000 cells or whether this peptide binds to the HLA with a structural modification such as central bulging or overhanging. The high peptide concentration requirement may be explained by multiple cysteine residues contained in the peptide, which cause formation of disulfide bonds in culture medium and interfere with HLA-peptide binding (36) . The low affinity of the peptide to the HLA-B*5502 molecule may be another possible reason for this requirement.

Wide expression of PBF in osteosarcomas and other sarcomas encourages the use of PBF-derived peptides in antisarcoma immunotherapy. In this regard, it remains to be determined whether PBF defined in tumors by RT-PCR and immunohistochemistry truly serves as an antigen. As we determined previously for other antigenic peptides (9 , 18) , CTL induction and tetramer analysis on peripheral blood mononuclear cells from patients with PBF-positive tumors are prerequisites for clinical use of PBF-derived peptides. Also, it is informative to investigate the impact of PBF expression on clinical behaviors of the tumor. Because PBF was detected in several normal tissues including pancreas and liver by RT-PCR analysis, potential autoimmunity against normal tissues may also be a concern. This needs to be evaluated preclinically by peptide immunization of HLA-transgenic mice. However, localization in the cytoplasm rather than the nucleus and the relatively weak expression of PBF in normal tissues appear to diminish such a likelihood. It should be noted that clinical studies of peptides derived from other ubiquitous antigenic proteins [i.e., WT1 (37) and HER-2/neu (38) ] have thus far reported no adverse effects related to autoimmunity.

Given the low prevalence of the HLA-B*5502 allele, the 12-mer antigenic peptide defined in this study is not widely clinically applicable. It is suitable to identify PBF-derived peptides that have high affinity to HLA-A2 and HLA-A24, common alleles in both Japanese and Caucasians. Our experience in an ongoing Phase I trial of SYT-SSX-derived peptide for HLA-A24-positive synovial sarcoma patients should benefit subsequent clinical applications of PBF-derived peptides. Those peptides with affinity to HLA-A2 and HLA-A24 may be applied as vaccine (s.c. injection) in patients with corresponding HLA and PBF-positive tumors.

In conclusion, this is the first report of identification of an antigenic peptide derived from osteosarcoma. PBF proven as an osteosarcoma antigen may serve as a source of peptides that are available for immunotherapy not only for osteosarcoma but also for other sarcomas. The current study has gone a long way toward proving that tumor-associated antigens are identifiable by the autologous pair-based approach from relatively low immunogenic and similarly low prevalence tumors. These above-stated identifications should further the development of efficacious immunotherapy for a diverse range of malignant tumors.


   ACKNOWLEDGMENTS
 
We thank Drs. H. Takasu, P. G. Coulie, B. Van den Eynde, F. Marincola, T. Nojima, and H. Sonobe for kind donation of synthetic peptides, cell lines, and hybridoma and Dr. Hisami Ikeda (Hokkaido Red Cross Blood Center) for generous help with the present study.


   FOOTNOTES
 
Grant support: Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan (Grant 15390462 to S. Kawaguchi; Grants 12213116, 15659097, and 16209013 to N. Sato); Japanese Orthopedic and Traumatology Foundation (Grant 0141 to S. Kawaguchi); and Japan Science and Technology Corporation (Grant H14-2 to N. Sato).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Satoshi Kawaguchi, Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, 060-8543 Japan. Phone: 81-11-611-2111, ext. 3333; Fax: 81-11-641-6026; E-mail: kawaguch{at}sapmed.ac.jp

Received 2/15/04. Revised 5/ 1/04. Accepted 6/ 3/04.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Arndt CA, Crist WM Common musculoskeletal tumors of childhood and adolescence. N Engl J Med, 341: 342-52, 1999.[Free Full Text]
  2. Bruland OS, Pihl A On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer, 33: 1725-31, 1997.
  3. van der Bruggen P, Zhang Y, Chaux P, et al Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev, 188: 51-64, 2002.[CrossRef][Medline]
  4. Rosenberg SA Progress in human tumour immunology and immunotherapy. Nature (Lond), 411: 380-4, 2001.[CrossRef][Medline]
  5. Slovin SF, Lackman RD, Ferrone S, Kiely PE, Mastrangelo MJ Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity. J Immunol, 137: 3042-8, 1986.[Abstract]
  6. Ogihara Y, Takeda K, Yanagawa T, Hirasawa Y Spontaneous regression of lung metastases from osteosarcoma. Cancer (Phila), 74: 2798-803, 1994.[CrossRef]
  7. Sabate JM, Llauger J, Torrubia S, Amores S, Franquet T Osteosarcoma of the abdominal wall with spontaneous regression of lung metastases. Am J Roentgenol, 171: 691-2, 1998.[Free Full Text]
  8. Nabeta Y, Kawaguchi S, Sahara H, et al Recognition by cellular and humoral autologous immunity in a human osteosarcoma cell line. J Orthop Sci, 8: 554-9, 2003.[CrossRef][Medline]
  9. Sato Y, Nabeta Y, Tsukahara T, et al Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma. J Immunol, 169: 1611-8, 2002.[Abstract/Free Full Text]
  10. Worley BS, van den Broeke LT, Goletz TJ, et al Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res, 61: 6868-75, 2001.[Abstract/Free Full Text]
  11. Sudo T, Kuramoto T, Komiya S, Inoue A, Itoh K Expression of MAGE genes in osteosarcoma. J Orthop Res, 15: 128-32, 1997.[CrossRef][Medline]
  12. Ishida H, Komiya S, Inoue Y, et al Expression of the SART1 tumor-rejection antigen in human osteosarcomas. Int J Oncol, 17: 29-32, 2000.[Medline]
  13. Sonobe H, Manabe Y, Furihata M, et al Establishment and characterization of a new human synovial sarcoma cell line, HS-SY-II. Lab Investig, 67: 498-505, 1992.[Medline]
  14. Nojima T, Wang YS, Abe S, et al Morphological and cytogenetic studies of a human synovial sarcoma xenotransplanted into nude mice. Acta Pathol Jpn, 40: 486-93, 1990.[Medline]
  15. Wada T, Uede T, Ishii S, et al Monoclonal antibodies that detect different antigenic determinants of the same human osteosarcoma-associated antigen. Cancer Res, 48: 2273-9, 1988.[Abstract/Free Full Text]
  16. Ikeda H, Lethe B, Lehmann F, et al Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity, 6: 199-208, 1997.[CrossRef][Medline]
  17. Maeda A, Ohguro H, Nabeta Y, et al Identification of human antitumor cytotoxic T lymphocytes epitopes of recoverin, a cancer-associated retinopathy antigen, possibly related with a better prognosis in a paraneoplastic syndrome. Eur J Immunol, 31: 563-72, 2001.[CrossRef][Medline]
  18. Nabeta Y, Sahara H, Suzuki K, et al Induction of cytotoxic T lymphocytes from peripheral blood of human histocompatibility antigen (HLA)-A31(+) gastric cancer patients by in vitro stimulation with antigenic peptide of signet ring cell carcinoma. Jpn J Cancer Res, 91: 616-21, 2000.[Medline]
  19. Hiraga H, Nojima T, Abe S, et al Diagnosis of synovial sarcoma with the reverse transcriptase-polymerase chain reaction: analyses of 84 soft tissue and bone tumors. Diagn Mol Pathol, 7: 102-10, 1998.[CrossRef][Medline]
  20. Kawaguchi S, Yamashita T, Yokogushi K, et al Immunophenotypic analysis of the inflammatory infiltrates in herniated intervertebral discs. Spine, 26: 1209-14, 2001.[CrossRef][Medline]
  21. Boeckle S, Pfister H, Steger G A new cellular factor recognizes E2 binding sites of papillomaviruses which mediate transcriptional repression by E2. Virology, 293: 103-17, 2002.[CrossRef][Medline]
  22. Dagher R, Long LM, Read EJ, et al Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol, 38: 158-64, 2002.[CrossRef][Medline]
  23. Pinilla-Ibarz J, Cathcart K, Korontsvit T, et al Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood, 95: 1781-7, 2000.[Abstract/Free Full Text]
  24. Korzeniewski C, Callewaert DM An enzyme-release assay for natural cytotoxicity. J Immunol Methods, 64: 313-20, 1983.[CrossRef][Medline]
  25. Decker T, Lohmann-Matthes ML A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods, 115: 61-9, 1988.[CrossRef][Medline]
  26. Lund AH, van Lohuizen M RUNX: a trilogy of cancer genes. Cancer Cell, 1: 213-5, 2002.[CrossRef][Medline]
  27. Ito Y, Miyazono K RUNX transcription factors as key targets of TGF-beta superfamily signaling. Curr Opin Genet Dev, 13: 43-7, 2003.[CrossRef][Medline]
  28. Lian JB, Balint E, Javed A, et al Runx1/AML1 hematopoietic transcription factor contributes to skeletal development in vivo. J Cell Physiol, 196: 301-11, 2003.[CrossRef][Medline]
  29. Nieda M, Nicol A, Kikuchi A, et al Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood, 91: 977-83, 1998.[Abstract/Free Full Text]
  30. Probst-Kepper M, Stroobant V, Kridel R, et al An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes. J Exp Med, 193: 1189-98, 2001.[Abstract/Free Full Text]
  31. Collins EJ, Garboczi DN, Wiley DC Three-dimensional structure of a peptide extending from one end of a class I MHC binding site. Nature (Lond), 371: 626-9, 1994.[CrossRef][Medline]
  32. Guo HC, Jardetzky TS, Garrett TP, et al Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle. Nature (Lond), 360: 364-6, 1992.[CrossRef][Medline]
  33. Schirmbeck R, Melber K, Reimann J Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I-restricted epitope presentation. Eur J Immunol, 25: 1063-70, 1995.[Medline]
  34. Schoel B, Zugel U, Ruppert T, Kaufmann SH Elongated peptides, not the predicted nonapeptide stimulate a major histocompatibility complex class I-restricted cytotoxic T lymphocyte clone with specificity for a bacterial heat shock protein. Eur J Immunol, 24: 3161-9, 1994.[Medline]
  35. Speir JA, Stevens J, Joly E, Butcher GW, Wilson IA Two different, highly exposed, bulged structures for an unusually long peptide bound to rat MHC class I RT1-Aa. Immunity, 14: 81-92, 2001.[CrossRef][Medline]
  36. Kittlesen DJ, Thompson LW, Gulden PH, et al Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. J Immunol, 160: 2099-106, 1998.[Abstract/Free Full Text]
  37. Oka Y, Udaka K, Tsuboi A, et al Cancer immunotherapy targeting Wilms’ tumor gene WT1 product. J Immunol, 164: 1873-80, 2000.[Abstract/Free Full Text]
  38. Murray JL, Gillogly ME, Przepiorka D, et al Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369–377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res, 8: 3407-18, 2002.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 GeneticsHome page
U. Yazdani, Z. Huang, and J. R. Terman
The Glucose Transporter (GLUT4) Enhancer Factor Is Required for Normal Wing Positioning in Drosophila
Genetics, February 1, 2008; 178(2): 919 - 929.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsukahara, T.
Right arrow Articles by Sato, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsukahara, T.
Right arrow Articles by Sato, N.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online